The Breast Cancer Aotearoa Coalition has dismissed Pharmac’s claims that cancer medicines funded in Australia but not New Zealand lack “meaningful” health gains.
The charity notes at least six breast cancer medicines that have significant health benefits for women with breast cancer that are funded in Australia, but not in New Zealand: Kadcyla, Perjeta, Abraxane, Faslodex, Afinitor, and Halaven.
The first-ever New Zealand forum dedicated to expanding knowledge about advanced breast cancer takes place in Auckland this week.
The Advanced Breast Cancer (ABC) Forum aims to provide “knowledge, support and empowerment” to those who have been diagnosed with advanced breast cancer, also known as secondary or metastatic breast cancer.
A Waikato study has found that Māori women wait longer for breast cancer surgery than New Zealand European women.
The longer delays for treatment are thought to be a significant contributing factor in the lower survival rates for Māori women compared with non-Māori in New Zealand.
Storage King NZ is turning pink this month to help support the Breast Cancer Aotearoa Coalition (BCAC) and the thousands of New Zealand women diagnosed with breast cancer each year.
Throughout October, Storage King NZ will donate $1 to BCAC from every tea chest sold and will transform its stores in a swathe of pink to promote Breast Cancer Action month.
BCAC is speaking out in support of the thousands of New Zealanders with metastatic breast cancer today: Secondary Breast Cancer Awareness Day.
Secondary breast cancer is cancer that has spread from the breast to other parts of the body, such as the bones, brain or liver. It is incurable.
BCAC chairperson, Libby Burgess, says thousands of women in New Zealand are living with secondary breast cancer and they deserve special recognition and support.
A recent study has found concerns about fertility stop one third of young women with breast cancer from taking tamoxifen despite its known benefit in reducing the risk of breast cancer returning.
The study, which was published in the Journal of the National Cancer Institute also found one quarter of women who started taking tamoxifen stopped taking it before the recommended treatment period ended.
The Eliminate trial will investigate whether combining two breast cancer treatments before surgery is more effective than one treatment alone for women with large and complex ER+ breast cancer.
New research from two studies has found postmenopausal patients with early stage breast cancer who take two types of drugs, aromatase inhibitors (such as Letrozole or Anastrozole) together with bisphosphonates, have better survival rates than those who don’t.
Results from the two studies were collated by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) group in the UK and published recently in The Lancet medical journal.
The latest innovation in fighting cancer has come to New Zealand and will be trialled in breast cancer patients from this month.
Immunotherapy, which is being used successfully to treat patients with melanoma, will now be trialled in patients with Triple Negative Breast Cancer (TNBC), a rare and aggressive form of breast cancer.